GlassScriptPhysician profile
Devina Shiwlochan
NPI 1326575242
$3,851.97
in general payments reported to CMS, 2019-2025
14 companies · $362 in 2025
The $362 reported for 2025 was more than what 89% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $321 · 2023: $2,208 · 2024: $330 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $1,875 · Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $1,875.00 |
| Food and Beverage | $1,024.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,875.00 | 2023 | Vercise |
| Medtronic, INC. | $654.25 | 2021-2025 | Shiley |
| Becton, Dickinson and Company | $260.20 | 2024-2025 | Hemosphere |
| Mml US, INC. | $253.35 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $231.79 | 2022-2023 | Iovera |
| Edwards Lifesciences Corporation | $201.37 | 2023-2024 | Hemosphere |
| Merck Sharp & Dohme LLC | $174.49 | 2023-2025 | Bridion |
| Mindray Ds USA, INC. | $73.43 | 2023-2025 | Te7 Max, Te X |
| Heron Therapeutics, INC. | $42.01 | 2024 | Aponvie |
| Csl Behring | $28.24 | 2023 | Kcentra |
| Cumberland Pharmaceuticals, INC. | $16.32 | 2024 | Caldolor |
| Eagle Pharmaceuticals, INC. | $14.54 | 2023 | |
| Masimo Corporation | $13.58 | 2023 | Sedline |
| Fujifilm Sonosite, INC. | $13.40 | 2023 | Sonosite Lx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devina Shiwlochan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.